Meeting
2020 ASCO Virtual Scientific Program
ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001.
Authors
Arlene O. Siefker-Radtke
The University of Texas MD Anderson Cancer Center, Houston, TX
Arlene O. Siefker-Radtke , Andrea Necchi , Se Hoon Park , Jesús García-Donas , Robert A Huddart , Earle Frederick Burgess , Mark T. Fleming , Arash Rezazadeh , Begona Mellado , Sergei Varlamov , Monika Joshi , Ignacio Duran , Scott T. Tagawa , Yousef Zakharia , Min Fu , Ademi E. Santiago-Walker , Manish Monga , Anne OHagan , Silvia Mosher , Yohann Loriot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Clinical Trial Registration Number
NCT02365597
Citation
J Clin Oncol 38: 2020 (suppl; abstr 5015)
DOI
10.1200/JCO.2020.38.15_suppl.5015
Abstract #
5015
Poster Bd #
84
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Impact of primary tumor location on efficacy and safety of pembrolizumab (pembro) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) enrolled in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-045 trials.
First Author: Peter H. O'Donnell
Poster
2021 Genitourinary Cancers Symposium
Management of fibroblast growth factor receptor inhibitor (FGFRi) treatment-emergent adverse events (TEAEs) of interest in patients (Pts) with locally advanced or metastatic urothelial carcinoma (mUC).
First Author: Arlene O. Siefker-Radtke
Poster
2023 ASCO Annual Meeting
Safety analysis by UGT1A1 status of TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI).
First Author: Yohann Loriot
Poster
2023 ASCO Annual Meeting
TROPHY-U-01 Cohort 4 (C4): Sacituzumab govitecan (SG) in combination with cisplatin (cis) as first-line (1L) therapy, followed by maintenance avelumab plus (+) SG or zimberelimab (zim) + SG in patients (pts) with treatment (Tx)-naïve metastatic urothelial cancer (mUC).
First Author: Chethan Ramamurthy